Fore Biotherapeutics Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 49

Employees

  • Latest Deal Type
  • Series D2

  • Latest Deal Amount
  • $38M

  • Investors
  • 16

Fore Biotherapeutics General Information

Description

Operator of a clinical-stage biotechnology company intended to develop selective medicines for functionally and gnomically defined cancer patients. The company's clinical-stage drug development aids in recapitulating naturally occurring mutations in vitro and tests their effect on signaling pathway activity and their response to different compounds, enabling biopharma companies to receive support in identifying new target mutations and expand subgroups of cancer patients to respond to existing therapies.

Contact Information

Website
www.fore.bio
Formerly Known As
NovellusDx
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3675 Market Street
  • Suite 200
  • Philadelphia, PA 19104
  • United States
+1 (267)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 3675 Market Street
  • Suite 200
  • Philadelphia, PA 19104
  • United States
+1 (267)

Fore Biotherapeutics Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Fore Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC (Series D2) 06-May-2025 $38M Completed Clinical Trials - Phase 2
9. Later Stage VC (Series D) 03-Jul-2024 Completed Clinical Trials - Phase 1
8. Secondary Transaction - Private 01-Jul-2023 Completed Clinical Trials - Phase 1
7. Later Stage VC (Series C) 21-Sep-2020 Completed Clinical Trials - Phase 1
6. Merger/Acquisition 17-Dec-2018 Cancelled Clinical Trials - Phase 1
5. Later Stage VC 30-Apr-2018 Completed Clinical Trials - Phase 1
4. Grant 31-Jan-2017 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series A) 22-Jun-2016 Completed Clinical Trials - Phase 1
2. Seed Round 01-Jan-2014 $1.14M $5.14M Completed Clinical Trials - Phase 1
1. Seed Round 01-Jul-2013 $4M $4M Completed Clinical Trials - Phase 1
To view Fore Biotherapeutics’s complete valuation and funding history, request access »

Fore Biotherapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D-2
Series D-1
Series D
Series C-1
Series C
Series B 54,869 $0.000010 8% $319.75 $319.75 1x $319.75 0.07%
Series A 6,706 $0.000010 8% $298 $298 1x $298 0.01%
To view Fore Biotherapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Fore Biotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage biotechnology company intended to develop selective medicines for functionally and gnomical
Drug Discovery
Philadelphia, PA
49 As of 2025

Gaithersburg, MD
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Fore Biotherapeutics Competitors (56)

One of Fore Biotherapeutics’s 56 competitors is NexImmune, a Formerly VC-backed company based in Gaithersburg, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Formerly VC-backed Gaithersburg, MD
Pyxis Oncology Formerly VC-backed Boston, MA
Cardiff Oncology Formerly Angel backed San Diego, CA
Aegle (Drug Discovery) Venture Capital-Backed Woburn, MA
NextCure Formerly VC-backed Beltsville, MD
You’re viewing 5 of 56 competitors. Get the full list »

Fore Biotherapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Fore Biotherapeutics Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
Medicxi Venture Capital Minority
Samsung Securities Corporation Minority
Cormorant Asset Management PE/Buyout Minority
HBM Healthcare Investments Venture Capital Minority
HBM Partners Venture Capital Minority
You’re viewing 5 of 16 investors. Get the full list »

Fore Biotherapeutics FAQs

  • When was Fore Biotherapeutics founded?

    Fore Biotherapeutics was founded in 2011.

  • Where is Fore Biotherapeutics headquartered?

    Fore Biotherapeutics is headquartered in Philadelphia, PA.

  • What is the size of Fore Biotherapeutics?

    Fore Biotherapeutics has 49 total employees.

  • What industry is Fore Biotherapeutics in?

    Fore Biotherapeutics’s primary industry is Drug Discovery.

  • Is Fore Biotherapeutics a private or public company?

    Fore Biotherapeutics is a Private company.

  • What is the current valuation of Fore Biotherapeutics?

    The current valuation of Fore Biotherapeutics is .

  • What is Fore Biotherapeutics’s current revenue?

    The current revenue for Fore Biotherapeutics is .

  • How much funding has Fore Biotherapeutics raised over time?

    Fore Biotherapeutics has raised $194M.

  • Who are Fore Biotherapeutics’s investors?

    Medicxi, Samsung Securities, Cormorant Asset Management, HBM Healthcare Investments, and HBM Partners are 5 of 16 investors who have invested in Fore Biotherapeutics.

  • Who are Fore Biotherapeutics’s competitors?

    NexImmune, Pyxis Oncology, Cardiff Oncology, Aegle (Drug Discovery), and NextCure are some of the 56 competitors of Fore Biotherapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »